Stocks · News reference

Propanc Biopharma Announces 1-for-10 Reverse Stock Split

Oct 23, 2026, 10:02 PM

Propanc Biopharma, Inc. has approved a 1-for-10 reverse stock split of its common stock, effective as of the market open on October 26, 2026, to maintain compliance with Nasdaq listing standards.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PPCB

Source: fiscal.ai
Observed: Oct 23, 2026, 10:02 PM
Checked: Oct 23, 2026, 10:03 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 16, 2026, 12:45 PMBenzinga News-desk
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
PPCB
BenzingaOct 14, 2026, 12:32 PMBenzinga Newsdesk
Propanc Biopharma Says Published Pilot Study Showed 85.9% Mean Tumor Weight Reduction With PRP In Pancreatic Cancer Animal Model
PPCB
BenzingaOct 7, 2026, 12:31 PMBenzinga Newsdesk
Propanc Biopharma Says PRP Shows Over 90% Tumor Growth Inhibition In Animal Models Of Pancreatic Cancer
PPCB

Propanc Biopharma Announces 1-for-10 Reverse Stock Split

Connected Markets

Related Headlines

Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer

Propanc Biopharma Says Published Pilot Study Showed 85.9% Mean Tumor Weight Reduction With PRP In Pancreatic Cancer Animal Model

Propanc Biopharma Says PRP Shows Over 90% Tumor Growth Inhibition In Animal Models Of Pancreatic Cancer